戊型肝炎：从幕后走到台前

吴健; 向泽; 曹红翠

doi:10.3969/j.issn.1001-5256.2023.11.001

戊型肝炎：从幕后走到台前

DOI: 10.3969/j.issn.1001-5256.2023.11.001

吴健^{1, 2},
向泽^{2, 3},
曹红翠^4, , ,

1.
苏州市立医院检验医学中心，江苏苏州 215008
2.
中国戊型肝炎研究协助组（CCSHE），江苏苏州 215008
3.
浙江大学医学院，杭州 310000
4.
浙江大学医学院附属第一医院传染病重症诊治全国重点实验室，国家感染性疾病临床医学研究中心，感染性疾病诊治协同创新中心，杭州 310003

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：吴健、向泽负责查找文献，撰写文稿；曹红翠负责审阅文稿及最后定稿。

详细信息

通信作者:
‍曹红翠， hccao@zju.edu.cn （ORCID： 0000-0002-6604-6867）

计量
- 文章访问数: 376
- HTML全文浏览量: 82
- PDF下载量: 157
- 被引次数: 0
出版历程
- 收稿日期: 2023-09-18
- 录用日期: 2023-10-19
- 出版日期: 2023-11-28

Hepatitis E： From behind the scenes to the front stage

Jian WU^{1, 2},
Ze XIANG^{2, 3},
Hongcui CAO^{4
, ,
,}

1.
Center of Laboratory Medicine，Suzhou Municipal Hospital，Suzhou，Jiangsu 215008，China
2.
Chinese Consortium for the Study of Hepatitis E，Suzhou，Jiangsu 215008，China
3.
Zhejiang University School of Medicine，Hangzhou 310000，China
4.
National Key Laboratory of Diagnosis and Treatment of Severe Infectious Diseases，National Clinical Research Center for Infectious Diseases，Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases，The First Affiliated Hospital，Zhejiang University School of Medicine，Hangzhou 310003，China

More Information

Corresponding author: CAO Hongcui， hccao@zju.edu.cn（ORCID： 0000-0002-6604-6867）

摘要

摘要: 戊型肝炎是由HEV感染引起的病毒性肝炎。HEV主要有4种基因型，分别为基因1～4型。相较乙型肝炎和丙型肝炎，既往戊型肝炎相关研究进展较为缓慢。然而，近年来我国对于戊型肝炎关注度逐步升高，实现了从幕后走向台前。首先，我国人口基数较大，HEV感染人数多，疾病负担较重，因而需高度重视戊型肝炎预防、诊断和治疗。其次，世界卫生组织提出“于2030年全球消除病毒性肝炎”的宏伟目标，我国在乙型肝炎和丙型肝炎防治现已取得卓越成效。目前，我国戊型肝炎发病率和病死率已超过甲型肝炎，对戊型肝炎的积极有效防治意义重大。最后，国内戊型肝炎领域研究者自发组成中国戊型肝炎研究协助组，制定相关专家共识，建立国内外合作平台，进一步推动我国戊型肝炎相关研究热潮。
- ‍戊型肝炎 /
- 公共卫生 /
- 诊断 /
- 治疗学
Abstract: Hepatitis E is a type of viral hepatitis caused by hepatitis E virus （HEV） infection. There are four main genotypes of HEV， namely genotypes 1‍ — ‍4. Compared with hepatitis B and hepatitis C， previous research on hepatitis E has made slow progress； however， in recent years， hepatitis E has gradually attracted more attention in China， achieving the transition from behind the scenes to the front stage. First， China has a large population base， a large number of people infected with hepatitis E， and a heavy disease burden， and thus it is necessary to attach great importance to the prevention， diagnosis， and treatment of hepatitis E. Second， the World Health Organization （WHO） has put forward the ambitious goal of eliminating viral hepatitis by 2030， and China has made remarkable achievements in the prevention and treatment of hepatitis B and hepatitis C. At present， the incidence and mortality rates of hepatitis E in China have exceeded those of hepatitis A， and the prevention and treatment of hepatitis E in China is of great significance to actively respond to the call of the WHO. Finally， Chinese researchers in the field of hepatitis E have formed Chinese Consortium for the Study of Hepatitis E， formulated related expert consensus， and established international cooperation platforms， which further promotes the research on hepatitis E in China.
- ‍Hepatitis E /
- Public Health /
- Diagnosis /
- Therapeutics

HTML全文

参考文献(10)

[1]	EMERSON SU, PURCELL RH. Hepatitis E virus[J]. Rev Med Virol, 2003, 13( 3): 145- 154. DOI: 10.1002/rmv.384.
[2]	KAMAR N, DALTON HR, ABRAVANEL F, et al. Hepatitis E virus infection[J]. Clin Microbiol Rev, 2014, 27( 1): 116- 138. DOI: 10.1128/CMR.00057-13.
[3]	KAMAR N, BENDALL R, LEGRAND-ABRAVANEL F, et al. Hepatitis E[J]. Lancet, 2012, 379( 9835): 2477- 2488. DOI: 10.1016/S0140-6736(11)61849-7.
[4]	LI PF, LIU JY, LI Y, et al. The global epidemiology of hepatitis E virus infection: A systematic review and meta-analysis[J]. Liver Int, 2020, 40( 7): 1516- 1528. DOI: 10.1111/liv.14468.
[5]	World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis[R]. Geneva: World Health Organization, 2016.
[6]	National Health Commission Center for Disease Control and Prevention. Action plan to eliminate the public health hazard of hepatitis C( 2021-2030)[EB/OL]. National Health Commission, 2021. http://www.nhc.gov.cn/jkj/s3586/202109/c462ec94e6d14d8291c5309406603153.shtml. http://www.nhc.gov.cn/jkj/s3586/202109/c462ec94e6d14d8291c5309406603153.shtml 国家卫生健康委员会疾病预防控制局. 消除丙型肝炎公共卫生危害行动工作方案( 2021- 2030 年)[EB/OL]. 国家卫健委, 2021. http://www.nhc.gov.cn/jkj/s3586/202109/c462ec94e6d14d8291c5309406603153.shtml. http://www.nhc.gov.cn/jkj/s3586/202109/c462ec94e6d14d8291c5309406603153.shtml
[7]	National Health Commission Center for Disease Control and Prevention. Overview of the national notifiable infectious disease epidemic in 2021[J]. Chin J Viral Dis, 2022, 12( 3): 236. 国家卫生健康委员会疾病预防控制局. 2021年全国法定传染病疫情概况[J]. 中国病毒病杂志, 2022, 12( 3): 236.
[8]	PAN QA, WEDEMEYER H. Global hepatitis E platform[Z]. 2022.
[9]	WU J, WANG Y. Introducing a Chinese consortium of hepatitis E[Z]. Global Hepatitis E Platform, 2022.
[10]	Chinese Consortium for the Study of Hepatitis E(CCSHE), Chinese Physician Association for Infectious Disease, National Clinical Research Center for Infectious Diseases. Expert consensus on the process of in-hospital screening and management of viral hepatitis E in China(2023)[J]. J Clin Hepatol, 2023, 39( 4): 785- 794. DOI: 10.3969/j.issn.1001-5256.2023.04.008. 中国戊型肝炎研究协助组(CCSHE), 中国医师协会感染科医师分会, 国家感染性疾病临床医学研究中心. 中国戊型病毒性肝炎院内筛查管理流程专家共识(2023年版)[J]. 临床肝胆病杂志, 2023, 39( 4): 785- 794. DOI: 10.3969/j.issn.1001-5256.2023.04.008.